One company faces regulatory setback while another achieves a Phase III victory, highlighting both urgency and uncertainty in …
One company faces regulatory setback while another achieves a Phase III victory, highlighting both urgency and uncertainty in …
Regulatory setback for one biotech contrasts with a major success in sleep disorder treatment, underscoring the high stakes …
A new international trial aims to confirm the benefit of adding masitinib to chemotherapy in men with metastatic …
Hope rises for patients with relapsed or refractory acute myeloid leukemia carrying the NPM1 mutation as revumenib moves …
New option opens for patients who have exhausted several therapies in their fight against relapsed or refractory multiple …
First biologic approved for this rare autoimmune blistering skin disease; pivotal trial data drive swift Priority Review.
Cycle Pharmaceuticals’ CEO calls approval “a defining moment for patients, physicians and science—proving unmet metabolic needs can be …
Once-monthly subcutaneous treatment offers new option for preventing hereditary angioedema attacks across all patient types from therapy initiation.
Clinical trial results underscore safety and diagnostic accuracy for radiopharmaceutical imaging; Clarity pursues regulatory filings and wider manufacturing …
This approval adds a key anti-inflammatory eye drop to Amneal’s Affordable Medicines portfolio, with a commercial launch planned …
Already a subscriber? Log in